Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Songjiang Ma | President & Chairman | -- | -- | 1956 |
| Dr. Han Ying Ph.D. | CEO & Director | 9.26k | -- | 1966 |
| Ms. Ruoyu Chen | Chief Financial Officer | 107.02k | -- | 1971 |
| Mr. Weiguo Ye | Chief Operating Officer | 242.19k | -- | 1978 |
Gyre Therapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 579
Description
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY, under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis. In addition, the company develops F573 is in Phase 2 clinical trials for the treatment of acute/acute-on-chronic liver failure. Further, its preclinical products include F230 for the treatment of pulmonary arterial hypertension; and F528 to treat chronic obstructive pulmonary disease. The company was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.
Corporate Governance
Upcoming Events
May 7, 2025 at 10:59 AM UTC - May 12, 2025 at 12:00 PM UTC
Gyre Therapeutics, Inc. Earnings Date
Recent Events
Recent Events Information Not Available